Approaches targeting autophagy and the cytoskeleton, including inhibition of METTL14 or modulation of FASN, provided combined inhibition of mTOR/ROS and decreased explant activity of RA-FLSs [62,63]. The gene discussed is MTOR; the disease is rheumatoid arthritis.